Progress and new standards of care in the management of HER-2 positive breast cancer

European Journal of Cancer

Volumn 43, Issue 3, 2007, Pages 497-509

  Demonty, Gaston ^a   Bernard Marty, Chantal ^a   Puglisi, Fabio ^b   Mancini, Isabelle ^a   Piccart, Martine ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b UNIVERSITY OF UDINE   (Italy)

Author keywords

Breast cancer; c erbB 2; Diagnosis; HER 2; Trastuzumab; Treatment

Indexed keywords

AROMATASE INHIBITOR; DOXORUBICIN; LETROZOLE; MONOCLONAL ANTIBODY; TAMOXIFEN; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CARDIOTOXICITY; CLINICAL TRIAL; DRUG DOSE REDUCTION; FEBRILE NEUTROPENIA; GENE AMPLIFICATION; GENE OVEREXPRESSION; HEART FAILURE; HUMAN; LOADING DRUG DOSE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; ONCOGENE NEU; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RR INTERVAL; SIDE EFFECT; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CENTRAL NERVOUS SYSTEM NEOPLASMS; GENES, ERBB-2; HUMANS; NEOADJUVANT THERAPY; RECEPTOR, ERBB-2;

EID: 33846627223     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.10.020     Document Type: Article

References (132)

1. American Cancer Society Facts and Figures 2005. Accessible in http://www.cancer.org.
2. World Health Organization Facts and Figures. Accessible in http://www.who.int.
3. Slamon D., Clark G., Wong S., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
4. Clarke P., te Poele R., Wooster R., and Workman P. Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential. Biochem Pharmacol 62 (2001) 1311-1336
5. Perou C., Sorlie T., Eisen M., et al. Molecular portraits of human breast tumours. Nature 406 (2000) 747-752
6. Sorlie T., Perou C., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98 (2001) 10869-10874
7. Sorlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100 (2003) 8418-8423
8. Sotiriou C., Neo S., McShane L., et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 100 (2003) 10393-10398
9. Yaziji H., Goldstein L., Barry T., et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 291 (2004) 1972-1977
10. Pauletti G., Dandekar S., Rong H., et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18 (2000) 3651-3664
11. Mass R., Press M., Anderson S., Murphy M., and Slamon D. Improved survival benefit from Herceptin (trastuzumab) in patients selected by fluorescence in situ hybridization (FISH). Proc Am Soc Clin Oncol (2001) 20 Abstract 85
12. Press M., Slamon D., Flom K., et al. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 20 (2002) 3095-3105
13. Larsimont D., Di Leo A., Rouas G., et al. HER-2/neu evaluation by immunohistochemistry and fluorescence in situ hybridization in breast cancer: implications for daily laboratory practice. Anticancer Res 22 (2002) 2485-2490
14. Tubbs R., Pettay J., Roche P., et al. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 19 (2001) 2714-2721
15. Seidman A., Fornier M., Esteva F., et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19 (2001) 2587-2595
16. Lebeau A., Deimling D., Kaltz C., et al. HER-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 19 (2001) 354-363
17. Roche P, Suman VJ, Jenkins RB, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 200;94:855-857.
18. Paik S., Bryant J., Tan-Chiu E., et al. Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 94 (2002) 852-854
19. Ellis I., Dowsett M., Bartlett J., et al. Recommendations for HER2 testing in the UK. J Clin Pathol 53 (2000) 890-892
20. Field A., Chamberlain N., Tran D., and Morey A. Suggestions for HER-2/neu testing in breast carcinoma, based on a comparison of immunohistochemistry and fluorescence in situ hybridisation. Pathology 33 (2001) 278-282
21. Schlemmer B., Sorensen B., Overgaard J., et al. Quantitative PCR-new diagnostic tool for quantifying specific mRNA and DNA molecules: HER2/neu DNA quantification with LightCycler real-time PCR in comparison with immunohistochemistry and fluorescence in situ hybridization. Scand J Clin Lab Invest 64 (2004) 511-522
22. Suo Z., Daehli K., Lindboe C., et al. Real-time PCR quantification of c-erbB-2 gene is an alternative for FISH in the clinical management of breast carcinoma patients. Int J Surg Pathol 12 (2004) 311-318
23. Gjerdrum L., Sorensen B., Kjeldsen E., et al. Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for HER-2/neu analysis. J Mol Diagn 6 1 (2004) 42-51
24. Raab G., Hoegel B., Biebl J., and Eiermann W. Chromogen in situ hybridisation (CISH) for HER2 assessment is highly concordant with FISH in core cut biopsies of primary T2 breast cancers. J Clin Oncol 22 (2004) 14s Abstract 569
25. Vera-Roman J., and Rubio-Martinez L. Comparative assays for the HER-2/neu oncogene status in breast cancer. Arch Pathol Lab Med 128 (2004) 627-633
26. Denoux Y., Arnould L., Fiche M., et al. HER2 gene amplification assay: is CISH an alternative to FISH?. Ann Pathol 23 (2003) 617-622
27. Vogel C., Cobleigh M., Tripathy D., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20 (2002) 719-726
28. Slamon D., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
29. Cobleigh M., Vogel C., Tripathy D., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17 (1999) 2639-2648
30. Baselga J., Tripathy D., Mendelsohn J., et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol 26 (1999) 78-83
31. Marty M., Cognetti F., Maraninchi D., et al. Randomized phase II trial of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23 (2005) 4265-4274
32. Pegram M., Lopez A., Konecny G., and Slamon D. Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin Oncol 27 6 Suppl 11 (2000) 21-25
33. Toi M., Sasaki Y., Tokuda Y., et al. Phase I/II study of trastuzumab (Herceptin) on pharmacokinetics and safety in combination with paclitaxel or docetaxel for metastatic breast cancer. Ann Oncol 13 Suppl 5 (2002) Abstract 182
34. Leyland-Jones B., Gelmon K., Ayoub J., et al. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 21 (2003) 3965-3971
35. Robert N., Leyland-Jones B., Asmar L., et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin versus trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer: An update including survival. J Clin Oncol 22 (2004) 14s Abstract 573
36. Fountzilas G., Tsavdaridis D., Kalogera-Fountzila A., et al. Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. A Hellenic Cooperative Oncology Group phase II study. Ann Oncol 12 (2001) 1545-1551
37. Krasna L., Janku F., Petruzelka L., Pribylova O., and Vedralova J. Herceptin (H) and Taxol (T) in the treatment of women with HER-2/neu overexpressing metastatic breast cancer (MBC): prospective study. Proc Am Soc Clin Oncol (2001) 20 Abstract 2006
38. Janku F., Pribylova O., Zimovjanova M., et al. 4-years results of weekly trastuzumab and paclitaxel in the treatment of women with HER2/neu overexpressing advanced breast cancer: single institution prospective study. Bull Cancer 91 (2004) 279-283
39. Gasparini G., Morabito A., De Sio L., et al. Preliminary clinical results of a randomized phase IIb study of weekly paclitaxel (PCT) trastuzumab (T) as first-line therapy of patients (pts) with HER2/neu positive metastatic breast cancer (MBC). Breast Cancer Res Treat 82 Supplement 1 (2003) Abstract 227
40. John M., Kriebel-Schmitt R., Stauch M., et al. Weekly paclitaxel plus trastuzumab shows promising efficacy in advanced breast cancer. Breast Cancer Res Treat 82 Supplement 1 (2003) Abstract 221
41. Fountzilas G., Tsavdaridis D., Kalogera-Fountzila A., et al. Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. A Hellenic Cooperative Oncology Group phase II study. Ann Oncol 12 (2001) 1545-1551
42. Yeung K., Gupta R., Haidak D., et al. Weekly (W) HerceptinR (H, traztuximab) and one hour Taxol (T, paclitaxel) infusion (WHT) regimen for human epidermal growth factor receptor-2 (HER2) overexpressed (+) metastatic breast cancer (MBC). Proc Am Soc Clin Oncol (2000) 19 Abstract 559
43. Kuzur M., Albain K., Huntington M., et al. A phase II trial of docetaxel and Herceptin in metastatic breast cancer patients overexpressing HER-2. Proc Am Soc Clin Oncol (2000) 19 Abstract 512
44. Bauer-Kosinska B, Lemanska I, Glogowska I, Sienkiewicz R, Pienkowski T. Efficacy and toxicity of docetaxel or cisplatin chemotherapy in combination with trastuzumab in the treatment of patients with chemotherapy pre-treated HER-2/neu overexpressed metastatic breast cancer. Eur J Cancer 1: S141 (Supplement 5). Abstract 464.
45. Montemurro F., Choa G., Faggiuolo R., et al. A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer. Oncology 66 (2004) 38-45
46. Tabei T., Kimura M., Sano M., et al. Multicenter phase II trial of three-weekly docetaxel and weekly trastuzumab in HER-2-overexpressing metastatic breast cancer patients: Japan East cancer center breast cancer consortium (JECBC 01 trial). Eur J Cancer 2 suppl 3 (2004) 131 Abstract 258
47. Raab G., Brugger W., Harbeck N., et al. Multicenter randomized phase II study of docetaxel (Doc) given q3w vs q1w plus trastuzumab (Tra) as first line therapy for HER2 overexpressing adjuvant anthracyclin pretreated metastatic breast cancer (MBC). Breast Cancer Res Treat 76 Supplement 1 (2002) Abstract 443
48. Meden H., Beneke A., Hesse T., Novophashenny I., and Wischnewsky M. Weekly intravenous recombinant humanized anti-P185HER2 monoclonal antibody (herceptin) plus docetaxel in patients with metastatic breast cancer: a pilot study. Anticancer Res 1 (2001) 1301-1305
49. Esteva F., Valero V., Booser D., et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20 (2002) 1800-1808
50. Schwartz G., Steis R., Mathew L., Gilkerson E., and Klein P. Patients with MBC prospectively selected by FISH derive clinical benefit from first-line treatment with Herceptin plus a taxane. Breast Cancer Res Treat 76 Supplement 1 (2002) Abstract 429
51. Raff J., Rajdev L., Malik U., et al. Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer. Clin Breast Cancer 4 (2004) 420-427
52. Takao S., Kohno N., Miyashita M., Kokufu I., and Wakita K. Weekly docetaxel and trastuzumab for HER-2-overexpressing metastatic breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study. Eur J Cancer 2 Supplement 3 (2004) 137 Abstract 302
53. Tedesco K., Thor A., Johnson D., et al. Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. J Clin Oncol 22 (2004) 1071-1077
54. Uber K., Nicholson B., Thor A., et al. A phase II trial of weekly docetaxel (D) and Herceptin (H) as first- or second-line treatment in HER2 over-expressing metastatic breast cancer. Proc Am Soc Clin Oncol (2001) 20 Abstract 1949
55. Burris H. Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer. Semin Oncol 28 Suppl 3 (2001) 38-44
56. Bangemann N., Kuhle A., Ebert A., et al. Capecitabine combined with trastuzumab in the therapy of intensively pretreated HER2 overexpressing metastatic breast cancer. Ann Oncol 11 suppl 4 (2000) Abstract 143
57. Yamamoto D., Iwase S., Kitamura K., and Odagiri H. Multicenter phase II study of trastuzumab (H) and capecitabine (X) as first- or second-line treatment in HER2 over-expressing metastatic breast cancer (Japan Breast Cancer Study Group: JBCSG-003). J Clin Oncol 23 (2005) 16s Abstract 802
58. Burstein H., Kuter I., Campos S., et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 19 (2001) 2722-2730
59. Chan A., Untch M., Petruzelka L., et al. Multinational phase II study of navelbine (N) and herceptin (H) as first-line therapy for HER2-overexpressing metastatic breast cancer (HER2 + MBC). Breast Cancer Res Treat 76 (2002) S112 Abstract 434
60. Burstein H., Harris L., Marcom P., et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 21 (2003) 2889-2895
61. Bernardo G., Palumbo R., Bernardo A., et al. Weekly Trastuzumab (Herceptin) and vinorelbine (Navelbine) in chemonaive patients with HER2-overexpressing metastatic breast cancer: A phase II trial. Annals of Oncology 13 Suppl. 5 (2002) 51
62. Jahanzeb M., Mortimer J.E., Yunus F., et al. Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer. Oncologist 7 (2002) 410-417
63. Papaldo P., Fabi A., Pino M., et al. Comparison between vinorelbine (V) in HER2-negative and vinorelbine plus trastuzumab (T) in HER2-positive pretreated metastatic breast cancer (MBC) patients (pts). Proc Am Soc Clin Oncol (2003) 22 Abstract 311
64. Bayo J., Mayordomo J., Sanchez Rovira P., et al. Trastuzumab and vinorelbine combination in the treatment of Her2 positive metastatic breast cancer. J Clin Oncol 22 (2004) 14s Abstract 763
65. Chan A., Petruzelka L., Untch M., et al. Long term survival of vinorelbine (N) and trastuzumab (H) as first line therapy for HER2-positive metastatic breast cancer patients (HER2 + MBC) (pts). J Clin Oncol 23 (2005) 16s Abstract 587
66. Filipovich E., Mayordomo J., Isla D., et al. Chemotherapy with trastuzumab plus vinorelbine in patients with erb-B2 overexpressed tumor is active in metastatic breast cancer. Breast Cancer Res Treat 76 Supplement 1 (2002) Abstract 436
67. Guillem Porta V., Martin M., Gil Gil M., et al. Evaluation of vinorelbine (N) and trastuzumab (H) as first-line therapy for patients (pts) with HER2- positive metastatic breast cancer (HER2 + MBC): Impact on clinical response and cardiac function. J Clin Oncol 22 (2004) 14s Abstract 363
68. Glogowska I., Jagiello-Gruszfeld A., Sienkiewicz-Kozlowska R., et al. The combination of trastuzumab and vinorelbine as a atractive regimen in overexpressing metastatic breast cancer patients. J Clin Oncol 23 (2005) 16s Abstract 3212
69. Franquesa R., Centelles M., Villadiego K., et al. A multicenter study of trastuzumab (H) and vinorelbine (N) as first and second line therapy for patients (pts) with HER2- positive metastatic breast cancer (HER2 + MBC). J Clin Oncol 23 (2005) 16s Abstract 868
70. O'Shaughnessy J., Vukelja S., Marsland T., et al. Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin Breast Cancer 5 (2004) 142-147
71. Christodoulou C., Fountzilas G., Razi E., et al. Gemcitabine and trastuzumab combination as salvage treatment in patients with HER 2-positive metastatic breast cancer. Proc Am Soc Clin Oncol (2003) 22 Abstract 166
72. Peacock N., Bearden J., Schnell F., et al. Phase II trial of gemcitabine plus trastuzumab in minimally pretreated HER2 overexpressing metastatic breast cancer. J Clin Oncol 23 (2005) 16s Abstract 704
73. Burris H., Yardley D., Jones S., et al. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. J Clin Oncol 22 (2004) 1621-1629
74. Nabholtz J., Pienkowski T., Nothfelt D., et al. Results of two open label Multicentre phase II pilot studies with Herceptin in combination with docetaxel and platinum salts (Cis or Carboplatin) (TCH) as Therapy for Advanced Breast Cancer (ABC) in women with tumors over-expressing the HER2-neu proto-oncogene. Eur J Cancer 31 (2001) 190
75. Polyzos A., Mavroudis D., Boukovinas J., et al. A multicenter phase II study of docetaxel, gemcitabine and trastuzumab administration as first-line treatment in patients with advanced breast cancer (ABC) overexpressing HER-2. J Clin Oncol 22 (2004) 14s Abstract 728
76. Miller K., Sisk J., Ansari R., et al. Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. Oncology (Huntingt) 15 Suppl 3 (2001) 38-40
77. Fountzilas G., Christodoulou C., Tsavdaridis D., et al. Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG). Cancer Invest 22 (2004) 655-662
78. Venturini M., Bighin C., Monfardini S., et al. Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat 95 (2006) 45-53
79. Perez E. Carboplatin in combination therapy for metastatic breast cancer. Oncologist 9 (2004) 518-527
80. Robert N., Leyland-Jones B., Asmar L., et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin versus trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer: An update including survival. J Clin Oncol 22 (2004) 14s Abstract 573
81. Seidman A., Hudis C., Pierri M., et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20 (2002) 1215-1221
82. Keefe D. Trastuzumab-associated cardiotoxicity. Cancer 95 (2002) 1592-1600
83. Keefe D. Erratum in: Cancer 97 (2003) 1136
84. Theodoulou M., Campos S., Batist G., et al. TLC D99 (D, Myocet) and Herceptin (H) is safe in advanced breast cancer (ABC): final cardiac safety and efficacy analysis. Proc Am Soc Clin Oncol (2002) 21 Abstract 216
85. Wolff A., Bonetti M., Sparano J., Wang M., and Davidson N. Cardiac safety of trastuzumab (H) in combination with pegylated liposomal doxorubicin (D) and docetaxel (T) in HER2-positive metastatic breast cancer (MBC): Preliminary results of the Eastern Cooperative Oncology Group trial E3198. Proc Am Soc Clin Oncol (2003) 22 Abstract 70
86. Cortes J., Climent M., Lluch A., et al. Updated results of a phase II study (M77035) of Myocet ccombined with weekly Herceptin and Paclitaxel in patients (pts) with HER2-positive locally advanced or metastatic breast cancer (LA/MBC). Breast Cancer Res Treat 88 Supplement 1 (2004) Abstract 3041
87. Chia K.S., Clemons M., Martin A., et al. A multi-centre phase II trial of pegylated liposomal doxorubicin and trastuzumab in HER-2 over-expressing metastatic breast cancer (MBC). J Clin Oncol 22 (2004) 14s Abstract 630
88. Plosker G., and Faulds D. Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs 45 (1993) 788-856
89. Untch M., Himsl I., Kahlert S., et al. Anthracycline and trastuzumab in breast cancer treatment. Oncology (Huntingt) 18 Suppl 14 (2004) 59-64
90. Bianchi G., Albanell J., Eiermann W., et al. Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer. Clin Cancer Res 9 (2003) 5944-5951
91. Leyland-Jones B. Dose scheduling-Herceptin. Oncology 61 Suppl 2 (2001) 31-36
92. Leyland-Jones B., Gelmon K., Ayoub J.P., et al. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 21 (2003) 3965-3971
93. Baselga J., Carbonell X., Castaneda-Soto N., et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 23 (2005) 2162-2171
94. Leyland-Jones B., Baselga J., Latreille J., Wardley A., and Lennon S. A novel loading regimen for trastuzumab in MBC: Boost serum levels in early cycles. J Clin Oncol 23 (2005) 16s Abstract 594
95. Gelmon K., Mackey J., Verma S., et al. Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer 5 (2004) 52-58
96. Fountzilas G., Razis E., Tsavdaridis D., et al. Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group. Clin Breast Cancer 4 (2003) 120-125
97. Bendell J., Domchek S., Burstein H., et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97 (2003) 2972-2977
98. Pansegrau G., Lohrisch C., Bajdik C., et al. A prognostic model to predict the risk of developing brain metastasis in patients treated with trastuzumab for HER-2 positive metastatic breast cancer. Breast Cancer Res Treat. 82 Supplement 1 (2003) Abstract 320
99. Lai R., Dang C., Malkin M., and Abrey L. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 101 (2004) 810-816
100. Clayton A., Danson S., Jolly S., et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 91 (2004) 639-643
101. Weitzen R., Zach L., Kaufman B., et al. High incidence of brain metastasis (BM) in patients on trastuzumab (H) for advanced breast cancer. Proc Am Soc Clin Oncol (2002) 21 Abstract 1936
102. Heinrich B., Brudler O., Siekiera W., Raab G., and Heinemann V. Development of brain metastasis in metastatic breast cancer (MBC) responding to treatment with trastuzumab. Proc Am Soc Clin Oncol (2003) 22 Abstract 147
103. Lower E., Blau R., Drosick D., et al. Brain metastases during Herceptin therapy: improved survival compared to patients not treated with Herceptin. Breast Cancer Res Treat 76 Supplement 1 (2002) Abstract 442
104. Altaha R., Crowell E., Hobbs G., Higa G., and Abraham J. Increased risk of brain metastases in patients with HER-2/neu-positive breast carcinoma. Cancer 103 (2005) 442-443
105. Dawson S., Ranieri N., Snyder R., et al. Trastuzumab (T) and CNS metastases in women with HER-2 positive metastatic breast cancer (MBC). J Clin Oncol 23 (2005) 16s Abstract 3212
106. Stemmler J., Kahlert S., Siekiera W., et al. Brain metastases (BM) in patients treated with trastuzumab for her2 overexpressing metastatic breast cancer (MBC): incidence and survival. J Clin Oncol 23 (2005) 16s Abstract 1568
107. Laufman L., and Forsthoefel K. Use of intrathecal trastuzumab in a patient with carcinomatous meningitis. Clin Breast Cancer 2 (2001) 235
108. Arteaga C., O'Neil A., Moulder S., et al. ECOG1100: a phase I-II study of combined blockade of the erbB receptor network with trastuzmab and gefitinib ([Isquo]Iressa') in patients (pts) with HER2-overexpressing metastatic breast cancer (met br ca). Breast Cancer Res Treat 88 Supplement 1 (2004) Abstract 25
109. Dang C., Dannenberg A., Subbaramaiah K., et al. Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments. Clin Cancer Res 10 (2004) 4062-4067
110. Storniolo A., Burris H., Pegram M., et al. A phase I, open-label study of lapatinib (GW572016) plus trastuzumab; a clinically active regimen. J Clin Oncol 23 (2005) 16s Abstract 559
111. De Laurentiis M., Arpino G., Massarelli E., et al. HER2 as predictive marker of resistance to endocrine treatment (ET) for advanced breast cancer (ABC): a metanalysis of published studies. Breast Cancer Res Treat 76 Supplement 1 (2002) Abstract 233
112. Winer E., Hudis C., Burstein H., et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23 (2005) 619-629
113. Goldhirsch A., Glick J., Gelber R., et al. Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005. Ann Oncol 16 (2005) 1569-1583
114. Ring A., and Dowsett M. Human epidermal growth factor receptor-2 and hormonal therapies: clinical implications. Clin Breast Cancer 4 Suppl 1 (2003) 34-41
115. Ellis M., Coop A., Singh B., et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19 (2001) 3808-3816
116. Burstein H., Harris L., Gelman R., et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 21 (2003) 46-53
117. Bines J., Murad A., Lago S., et al. Multicenter brazilian study of weekly docetaxel and trastuzumab as primary therapy in stage III, HER-2 overexpressing breast cancer. Proc Am Soc Clin Oncol (2003) 22 Abstract 268
118. Moluçon C., Vanlemmens L., Chollet P., et al. Pathological complete response with neoadjuvant (NA) chemotherapy (trastuzumab (T) and docetaxel (D)) in HER2 positive (3+) locally advanced (LA) breast cancer (BC) patients. Breast Cancer Res Treat 82 Supplement 1 (2003) Abstract 253
119. Schiffhauer L., Griggs J., Ahrendt G., and Sorbero M. Docetaxel and trastuzumab as primary systemic therapy for HER-2/neu-overexpressing breast cancer. Proc Am Soc Clin Oncol (2003) 22 Abstract 969
120. Harris L., Burstein H., Gelman R., et al. Preoperative trastuzumab and vinorelbine (HN) is a highly active, well-tolerated regimen for HER2 3+/FISH+ Stage II/III breast cancer. Proc Am Soc Clin Oncol (2003) 22 Abstract 86
121. Hurley J., Doliny P., Silva O., et al. Neoadjuvant herceptin/taxotere/cisplatin in the treatment of locally advanced and inflammatory breast cancer. Proc Am Soc Clin Oncol (2002) 21 Abstract 196
122. Steger G., Wenzel C., Locker G., et al. Pilot-trial of trastuzumab + weekly epidoxorubicin / docetaxel in the neoadjuvant treatment of primary breast cancer - preliminary results. Proc Am Soc Clin Oncol (2002) 21 Abstract 1966
123. Griggs J., Schiffhauer L., Sahasrabudhe D., et al. Safety and effectiveness of primary systemic therapy with docetaxel and trastuzumab in HER-2 positive breast cancer. J Clin Oncol 23 (2005) 16s Abstract 793
124. Jahanzeb M., Brufsky A., Erban J., Lewis D., and Limentani S. Dose-dense neoadjuvant treatment of women with breast cancer utilizing docetaxel, vinorelbine and trastuzumab with growth factor support. J Clin Oncol 23 (2005) 16s Abstract 591
125. Buzdar A., Ibrahim N., Francis D., et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23 (2005) 3676-3685
126. Geyer Jr. C., Bryant J., Romond E., et al. Cardiac safety analysis of the first stage of NSABP B-31, a randomized trial comparing the safety and efficacy of Adriamycin and cyclophosphamide (AC) followed by Taxol to that of AC followed by Taxol plus Herceptin in patients (Pts) with operable, node-positive (N+), HER-2 overexpressing breast cancer (HER2 + BC). Breast Cancer Res Treat 82 Supplement 1 (2003) Abstract 23
127. Romond E., Perez E., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
128. Piccart-Gebhart M., Procter M., Leyland-Jones B., et al. Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 (2005) 1659-1672
129. Slamon D., Eiermann W., Robert N., et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC → T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC → TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 94 Supplement 1 (2005) Abstract 1
130. Joensuu H., Kellokumpu-Lehtinen P., Bono P., et al. Trastuzumab in combination with docetaxel or vinorelbine as adjuvant treatment of breast cancer: the FinHer Trial. Breast Cancer Res Treat 94 Supplement 1 (2005) Abstract 2
131. Miller K. The role of ErbB inhibitors in trastuzumab resistance. Oncologist 9 Suppl 3 (2004) 16-19
132. Cardoso F., Piccart M., Durbecq V., and Di Leo A. Resistance to trastuzumab: a necessary evil or a temporary challenge?. Clin Breast Cancer 3 (2002) 247-257